management of clinical trials: sponser perspective from falgun vyas
DESCRIPTION
TRANSCRIPT
Conduct of clinical trials: an overview:
Sponsor perspective
07:54 AM
Outlines of the presentation
Standard Operating Procedures (SOPs) for clinical trial
Protocol – a brief overviewSelection of Clinical investigator Investigator training (during SIV and
meeting)Periodic monitoring Audits/ inspections
07:54 AM
07:54 AM
SOPs for clinical trial
“Detailed, written instructions to achieve uniformity of the performance of a specific function".
Majority of penalties from regulatory authority imposed due to the carelessness which is a byproduct of not following SOPs in performing clinical trials.
07:54 AM
SOPs answers
- 4 Ws and H concept of clinical trial management
SOP should be prepared
with utmost care
and then it should be
followed religiously
who
what
when
where
how
07:54 AM
Objectives of SOPs
Standardize the working practices
Improve and maintain the quality of operations
Ensures quality, consistent and reproducible results
Defines the methodology to be followed
Defines the roles and responsibilities of the individuals
Ensures compliance to regulatory guidelines
Saves times 07:54 AM
Effective SOP should
Simple, easy to understand
Comprehensive
Differentiate between instructions and general
information
Describe procedure in a familiar way
Descriptive title07:54 AM
Protocol: definition
“A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial.”
Background and rationale for study allows researchers at multiple locations to
perform the study in same way, so that their data can be combined
07:54 AM
Protocol: the plan; at the heart of every trial
Organizations have their own format Generated from a standard template, which
complies with regulatory requirements and company policy
‘copied and pasted’ from a previous protocol avoid repetition in multiple sections Better to have protocol review boards with
representatives from QA, data management, physician and statistician.
07:54 AM
Protocol
After approval of the protocol by the ethics committee and the regulatory authority, any changes must be documented.
Signed off by a senior representative of the medical department, the statistician & a medical advisor
Professional responsibility for the content Each individual investigator will sign the
protocol, thereby agreeing to comply with it07:54 AM
Protocol amendments
Minor: known as protocol revisions or administrative amendments
no impact on risks, clinical decision-making
Major: more significant inclusion/exclusion criteria, a lab test & changes
to definition of what constitutes an AE Any change must be submitted to an IRB. Some
IRBs merely acknowledge their receipt, while others actively review & approve changes
07:54 AM
Protocol Deviation
any change, divergence, or departure from the study design or procedures
Failure of subject to return unused study drug Participant is seen outside of the visit “window” Participant forgets to take 1 dose of study
medication
07:54 AM
Protocol Violation
Deviation that affect the subject's rights, safety, or well being and/or accuracy and reliability of the study data.
Failure to obtain prior informed consent/inadequate or improper consent procedure
Enrolled not meet eligibility criteria Withdrawal criteria met but not withdrawn Wrong treatment/dose Excluded concomitant medication Failure to follow protocol related to primary efficacy outcomes Loss of samples/data Repeated minor deviations A breach of confidentiality
07:54 AM
Minor protocol deviations- NO RISK
any change from study protocol-not been approved by the IRB and which DOES NOT have a major impact
only logistical or administrative aspects of the trial (e.g. change in monitor(s), change of telephone number(s)).
07:54 AM
Reporting of protocol deviations
Protocol violation should be reported within __ days of the investigator’s knowledge of the deviation. Reports should be made using the Deviation Report Form
Protocol deviation documented in the study file; not need to be submitted to the EC as they occur-annual study status report to EC and at final study closure.
Subject-specific waiver from sponsor07:54 AM
Selection of an investigator and site pre-assessment
Objectives of Site Selection Assessment of potential problems Budget estimate Concerns about site / investigator Decision about conduct / site
Investigator = Protective Physician + Responsible Researcher
07:54 AM
Selection Process
Identifying Potential Investigators Marketing department Literature Review Medical society directories Reference from investigator Professional colleagues Clinical trial registries
Potential
investigators
Criteria for
evaluation
Report
Feasibility study
07:54 AM
Investigator Facility Protocol feasibility
Qualifications Appropriateness Availability of potential subjects
License Storage facilities Interest level
Specialty Special equipment Study coordinator availability
Clinical trial experience Active practice Attendance of investigator meeting
FDA audits EC availability Competing studies
Site evaluation
07:54 AM
SELECT criteria
07:54 AM
Knowledge & Skills for Feasibility Study
Knowledge
Disease Drug Design Protocol GCP SOPs Investigator Literature search
Skills
Business etiquette Communication Decision making Interpersonal Planning Time management Negotiation Computer
07:54 AM
Feasibility Study
Questionnaire Initial contact – phone / email Visit Report Discussion Decision
Selection of Site is Art Of Investigating
Investigator07:54 AM
Investigator meeting and training
sponsorreg
ulatoryvoluntee
rEthics
committee
07:54 AM
Difference between practice and research
Practice ≠
- exercise of an occupation or a profession– No protocol– Administer to all
patients– Some documentation– Not intended to
publish
Research
– systematic investigation designed to contribute to generalizable knowledge – Protocol– Administer to some
patients– Much documentation– Intend to publish
07:54 AM
Investigator training
Ethically, legally & clinically responsible for the conduct of study
PIs primary clinicians routinely claim to be busy to attend training, not be allowed to conduct
GCP training responsibility of sponsor- GCP noncompliance linked to inadequate training.
Sponsors and EC each having authority to mandate GCP training as a prerequisite
In US, holds IRBs accountable for dismal state of investigator GCP training!! 07:54 AM
Challenges with investigator training
Busy investigator Coordinators can be trained in the GCP training
several times but investigators not finding time Coordinator training is not surrogate Not understanding the importance ”what’s in it
for me”? Poor past history
Experienced investigator “oh, I know all about that.”
07:54 AM
Investigator meeting
Complex protocols, new technologies and increased regulatory scrutiny have all made study execution more challenging
Amount of information a site must understand about a protocol is enough to make one's head spin. Moreover, sites participating in several studies; a lot of room for error
Primary goal of meeting-- improve the performance of study site staff and ensure quality of data
Ultimate purpose of the investigator meeting: to enable the safe and effective execution of a study protocol.
07:54 AM
Make meetings better and more effective
Improved and simplified agendas, Increased interactivity, Shorter meetings, Less travel time, Enhanced speaker performance and An elimination of training redundancies. Start with training outcomes in mind and plan their
meetings around those stated goals. Incorporating adult learning techniques such as
interactive case studies or break out sessions07:54 AM
eLearning alternatives
Saves time and at the same time provide a self-paced and effective training
Can be used to track who has completed and, comprehended the training and allow the sponsor to retain training records thus addressing potential compliance issues
07:54 AM
Optimal solution: in-person meetings and eLearning
Both. i.e. experienced investigators-eLearning, while inexperienced investigators & coordinators-in person
Another option everyone’s GCP training via eLearning, & then a shorter, more focused protocol specific meeting
After training no resources to draw any output- only field monitors-this run the risk of allowing to forget much
Turnover among site (or sponsor) staff, namely ensuring that everyone receives the same training
Benefits of continuous education: higher quality data, better performing sites, enhanced site relationships, and significant cost and time savings.
07:54 AM
Informed consent
07:54 AM
Informed consent process
Investigator’s Responsibility Continuous process
– starts with initial presentation of research activity – continues until the subject participation ends
present the information accurately In a manner minimizing the possibility of
coercion or undue influence
07:54 AM
Methods to improve consent process
To record the consent process using recorders
Consent for recording consent QuIC-
Questionnaire to measure subjects' actual vs. perceived understanding of CT what it includes: basic elements,
therapeutic misconception,
language and structure Group discussion Giving documents well in advance
07:54 AM
Documentation of the Informed Consent Process:
Check all that apply The subject meets all eligibility requirements.
Discussed, explained and reviewed the consent form with subject.- add time schedule
Verbal consent/ Surrogate consent was obtained (per IRB approved consent process)
All of the subject’s questions were answered/concerns addressed. (document multiple subject question)
Subject did not have any questions/concerns
07:54 AM
Documentation of the Informed Consent Process:
Subject was given time to review the consent form and to discuss participation in this study with family members/others.
The subject has agreed to participate in study & signed/dated a valid consent form prior to the start of any study procedures.
The consent process was witnessed by a third party (if applicable).
Witnessed by:
A copy of the signed and dated consent form was given to the subject.
A copy of the signed and dated consent form was placed in the medical record/ research record.
Documentation of other conversation
07:54 AM
Monitoring of trial: Difference between QC and QA
QC
the operational techniques and activities undertaken by all; to verify that the quality requirements fulfilled
Includes checks that the data recorded are consistent with source documents; correct dose administered & SOPs and protocol are followed
QA
Verifies that the QC has satisfied these requirements.
Includes the establishment of SOPs that oblige staff to follow uniform practice, and checks that QC is in place and is effective.
07:54 AM
Periodic monitoring: Objectives
1) Documentation of Informed Consent Process.
2) Protocol enrollment eligibility criteria
3) Data entry is complete & consistent between CRFs and source Documents.
4) IP Accountability- accurately documented
5) Ensure Laboratory procedures documented
6) Ensure compliance of all Essential Regulatory Documents per regulations
07:54 AM
The intensity of monitoring
Vary across studies and among sites Who will monitor-
– sponsor’s SOPs, – the complexity of the protocol,– condition being studied, – the experience of the investigator and – the training and experience of the CRA
Overall plan remain fairly consistent,
but strategy for individual sites may change depending on study conditions and site performance
07:54 AM
Frequency of monitoring visits
Complexity of protocol Disease being evaluated Experience of the investigator/staff Number of study subjects enrolled at the site Rate of enrollment Site performance Sponsor monitoring SOPs CRA experience and effectiveness
07:54 AM
Monitoring activity
General plan for what will be monitored at each site visit
Most sponsors have a site visit or monitoring report-which is a standard document that a CRA will use for all field monitoring visits
Serves as both a checklist for the CRA and as documentation of the visit.
However, the CRA must not view this as the only list of activities that must be done.
07:54 AM
Top 5 deficiency categories for site inspections
1. Failure to follow the protocol
2. Failure to keep adequate and accurate records
3. Problems with the informed consent form
4. Failure to report adverse events
5. Failure to account for the disposition of study drugs
07:54 AM
Audits
A Systematic and independent examination of trial related activities and documents to determine whether the evaluated trial related activities were conducted and the data were recorded, analysed and accurately reported according to the
- Protocol, - Sponsor’s SOP - Good Clinical Practice and - Applicable Regulatory requirement
07:54 AM
What is difference betweenAudit and Inspection
Audit
Inspectors of the company who work for a active clinical quality assurance (CQA) function (i.e. Sponsor/CRO)
To ensure that a site is complying with Protocol, SOP, GCP and Applicable regulatory requirements.
Inspection
Inspector by government, through the agency of the regulatory or competent Authority (i.e. FDA/DCGI)
To ensure that trial related obligations and acceptability of resultant clinical data is in support of a new drug approval.
07:54 AM
Monitoring
continuous process i.e. it is a part of the study,
done for each and every site and for every subject, 100% for each activity
Responsibility of the Sponsor only,
Monitoring is Quality Control
Auditing
not a continuous process, it may or may not happen
few sites and selected subjects; samples
done by Regulatory body as well as sponsor
Auditing is Quality Assurance
07:54 AM
What can be Audited:
Site Investigators and Study Team IRB/IEC Sponsor CRO, if involved Laboratories Pharmacy (e.g. Investigational Drug Services) Devices (e.g. ECG, Biomedical, Engineering)
07:54 AM
How they select site:
Study oriented audits:
– Patient Enrollment: Highest enrolling sites
– Patient Retention: Large no. of screen failures, drop-out rates
– AE: Large no. of SAE at only 1/2 sites
– Trial Importance: Pivotal studies.
Investigator oriented audits
generally occur when the drug regulatory authority has cause to suspect particular research’s conduct i.e. “For-cause Audit”
07:54 AM
Audit Procedure
Audit plan/Agenda Notify conduct of audit to CRA and Site present their credentials (photo ID) & a Notice
of Inspections Form Introductory Meeting start auditing by reviewing specific data interview site staff directly involved in trial
activities and process Closing meeting (exit interview)
07:54 AM
How to select sample no. of CRFs for SDV
square root of number of CRFs plus one (screened/randomized)
a minimum range-3-5 CRFs. 100 % SDV for ICFs and then 100 % of SDV
for 10 % of total CRFs. all primary efficacy data and AE would be
audited 100% for all patients randomized and/ or enrolled.
If particular problems found then07:54 AM
Auditor’ s common observations for study
1. Protocol Non-adherence
2. Inadequate & inaccurate records
3. Failure to report adverse events
4. Failure to report concomitant Rx
5. Inadequate drug accountability
6. IRB/IEC problems
7. Informed Consent issues
07:54 AM
After Audit Procedure:
After the Audit is complete, the Auditor prepare an Audit certificate Audit report / Establishment Inspection Report
(EIR):Classification Type of Letter
NAI (No Action Indicated) Notice of no significant deviations
VAI (Voluntary Action Indicated) Informational
OAI (Official Action Indicated) Warning
07:54 AM
Thank you any??
07:54 AM